June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Excimer Ablation of Collagen-Based Corneal Substitutes
Author Affiliations & Notes
  • Silvia Odorcic
    The Ottawa Hospital, Ottawa, ON, Canada
  • Christopher Noel
    The Ottawa Hospital, Ottawa, ON, Canada
  • Debbie Mitra
    The Ottawa Hospital, Ottawa, ON, Canada
  • David Priest
    The Ottawa Hospital, Ottawa, ON, Canada
  • Sabrina Taylor
    The Ottawa Hospital, Ottawa, ON, Canada
  • May Griffith
    Linköping University, Linköping, Sweden
  • Rejean Munger
    The Ottawa Hospital, Ottawa, ON, Canada
  • W. Bruce Jackson
    The Ottawa Hospital, Ottawa, ON, Canada
  • Footnotes
    Commercial Relationships Silvia Odorcic, None; Christopher Noel, None; Debbie Mitra, None; David Priest, None; Sabrina Taylor, Allergan Canada (C); May Griffith, Univ. of Ottawa - OHRI (P); Rejean Munger, None; W. Bruce Jackson, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4683. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Silvia Odorcic, Christopher Noel, Debbie Mitra, David Priest, Sabrina Taylor, May Griffith, Rejean Munger, W. Bruce Jackson; Excimer Ablation of Collagen-Based Corneal Substitutes. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4683.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Biosynthetic corneal hydrogels have already undergone successful implantation in human patients with keratoconus and may one day serve as useful alternatives to human donor tissue for surgical and refractive procedures. For synthetic materials to be biocompatible, they should undergo laser ablation in a consistent and reproducible manner. The purpose of our study was 1) to determine the feasibility and consistency of excimer ablation of collagen-based corneal biomimics (hydrogels), 2) to compare the ablation rates of hydrogels with different mechanical properties.

Methods: Twelve samples of four different hydrogel formulations (10% recombinant porcine collagen) underwent identical excimer ablations (125 µm PTK, 6.0 mm). All hydrogels were cross-linked using a carbodiimide (EDC), epoxy-based cross-linker (BDDGE) or combination (hybrid) to enhance their mechanical properties. Hydrogel ablations were captured using a specialized high resolution camera (optical profilometer). Custom software was used to extract ablation rates by analyzing silhouette images of hydrogels undergoing ablation.

Results: All hydrogels were amenable to excimer ablation. Ablation rate was plotted against total ablation time for all samples. Hydrogels cross-linked with EDC exhibited extremely consistent ablation rates with minimal inter-sample variability during all time points relative to total ablation time. Hybrid hydrogels (EDC+BDDGE) exhibited moderate ablation consistency between samples, while those cross-linked with BDDGE alone displayed the poorest consistency in ablation rates. The ablation rate of hybrid hydrogels was almost twice as fast as that of EDC cross-linked samples. Hybrid hydrogels also had the most optimized mechanical properties (highest tensile strength and elasticity).

Conclusions: Cross-linked biosynthetic hydrogels can undergo excimer ablation and therefore fulfill one important requirement of synthetic corneal substitutes: biocompatibility. By tailoring the hydrogel’s mechanical properties through cross-linking, ablation rates can also be manipulated. Our hybrid hydrogels have the highest tensile strength and elasticity, as well as the fastest ablation rates of all samples tested. Such properties contribute to enhanced suturability and post-implantation healing. In the future, corneal hydrogels may supplement human donor corneas with tissue-engineered alternatives.

Keywords: 578 laser • 480 cornea: basic science • 678 refractive surgery  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×